Equillium Maintains Rights to Itolizumab Following Ono Partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Jones Trading Downgrades Equillium (EQ) to Hold
October 31, 2024 4:29 PM EDTJones Trading analyst Catherine Novack downgraded Equillium (NASDAQ: EQ) from Buy to Hold.
The analyst comments: What's new: Equillium announced that Ono Pharmaceutical (OPHLY, Not Rated) declined the option to acquire itolizumab (press release). Equillium now has full commercial rights to ito, but there... More
